Terms: = Ovarian cancer AND CBFA2T3, ETO2, 863, ENSG00000129993, ZMYND4, MTGR2, MTG16 AND Diagnosis
12 results:
1. diagnosis Shift in Site of Origin of Tubo-ovarian Carcinoma.
Lee MW; Anderson ZS; Girma AM; Klar M; Roman LD; Carlson JW; Wright JD; Sood AK; Matsuo K
Obstet Gynecol; 2024 May; 143(5):660-669. PubMed ID: 38513238
[TBL] [Abstract] [Full Text] [Related]
2. A blood-based metabolomic signature predictive of risk for pancreatic cancer.
Irajizad E; Kenney A; Tang T; Vykoukal J; Wu R; Murage E; Dennison JB; Sans M; Long JP; Loftus M; Chabot JA; Kluger MD; Kastrinos F; Brais L; Babic A; Jajoo K; Lee LS; Clancy TE; Ng K; Bullock A; Genkinger JM; Maitra A; Do KA; Yu B; Wolpin BM; Hanash S; Fahrmann JF
Cell Rep Med; 2023 Sep; 4(9):101194. PubMed ID: 37729870
[TBL] [Abstract] [Full Text] [Related]
3. Seeing beyond the tumor: computed tomography image-based radiomic analysis helps identify ovarian clear cell carcinoma subtype in epithelial ovarian cancer.
Ren J; Mao L; Zhao J; Li XL; Wang C; Liu XY; Jin ZY; He YL; Li Y; Xue HD
Radiol Med; 2023 Aug; 128(8):900-911. PubMed ID: 37368228
[TBL] [Abstract] [Full Text] [Related]
4. Predictors of malignancy in incidental adnexal lesions identified on CT in patients with prior non-ovarian cancer.
Shinagare AB; Gujrathi I; Cochon L; Burk KS; Sadowski E; Khorasani R
Abdom Radiol (NY); 2022 Jan; 47(1):320-327. PubMed ID: 34468797
[TBL] [Abstract] [Full Text] [Related]
5. Long Noncoding RNA LINC01554 as a Novel Biomarker for diagnosis and Prognosis Prediction of Epithelial ovarian cancer.
Luo T; Jiang Y; Yang J
Dis Markers; 2021; 2021():1244612. PubMed ID: 34422133
[TBL] [Abstract] [Full Text] [Related]
6. [Bioinformatics analysis of drug-resistant ceRNA in epithelial ovarian cancer].
Pan ZM; Tan FC; Chen CX; Zhang W; Li L
Zhonghua Fu Chan Ke Za Zhi; 2021 Feb; 56(2):121-130. PubMed ID: 33631884
[No Abstract] [Full Text] [Related]
7. Assessment of diagnostic utility of multivariate diagnostic models in differential diagnosis of ovarian tumors.
Horała A; Swiatly A; Lorek J; Kokot ZJ; Matysiak J; Nowak-Markwitz E
Ginekol Pol; 2018; 89(10):568-572. PubMed ID: 30393846
[TBL] [Abstract] [Full Text] [Related]
8. The Safety of ovarian Preservation in Stage I Endometrial Endometrioid Adenocarcinoma Based on Propensity Score Matching.
Hou T; Sun Y; Li J; Liu C; Wang Z; Li Y; Lu Y
Comb Chem High Throughput Screen; 2017; 20(7):647-655. PubMed ID: 28413975
[TBL] [Abstract] [Full Text] [Related]
9. Molecular status of PI3KCA, KRAS and BRAF in ovarian clear cell carcinoma: an analysis of 63 patients.
Zannoni GF; Improta G; Pettinato A; Brunelli C; Troncone G; Scambia G; Fraggetta F
J Clin Pathol; 2016 Dec; 69(12):1088-1092. PubMed ID: 27153872
[TBL] [Abstract] [Full Text] [Related]
10. CA19-9 elevation in ovarian mature cystic teratoma: discrimination from ovarian cancer - CA19-9 level in teratoma.
Cho HY; Kim K; Jeon YT; Kim YB; No JH
Med Sci Monit; 2013 Mar; 19():230-5. PubMed ID: 23539074
[TBL] [Abstract] [Full Text] [Related]
11. Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer-a clinical and pathological evaluation.
Voss MA; Ganesan R; Ludeman L; McCarthy K; Gornall R; Schaller G; Wei W; Sundar S
Gynecol Oncol; 2012 Jan; 124(1):15-20. PubMed ID: 21864888
[TBL] [Abstract] [Full Text] [Related]
12. Lung cancer risk following detection of pulmonary scarring by chest radiography in the prostate, lung, colorectal, and ovarian cancer screening trial.
Yu YY; Pinsky PF; Caporaso NE; Chatterjee N; Baumgarten M; Langenberg P; Furuno JP; Lan Q; Engels EA
Arch Intern Med; 2008 Nov; 168(21):2326-32; discussion 2332. PubMed ID: 19029496
[TBL] [Abstract] [Full Text] [Related]
